Research
Hormonal
Chronic low-grade inflammation, driven by obesity and excess nutrient intake, is a primary mechanistic link that causes both insulin resistance and hypertension by impairing insulin signaling and promoting vasoconstriction.
Addressing the root cause of inflammation through weight management and reducing processed food intake can simultaneously improve insulin sensitivity and lower blood pressure, as inflammation drives both pathologies.
GoodSupportsHIGH confidence
When the capacity for safe lipid storage in adipose tissue is exceeded lipids overflow to non-adipose tissue, increasing the risk for chronic systemic low grade inflammation and subsequent insulin resistance, hypertension and metabolic syndrome.
Why this rating
Supported by multiple cited studies on animal models (Dahl salt-sensitive rats) and clinical observations of inflammatory markers.
Source
Link between insulin resistance and hypertension: What is the evidence from evolutionary biology?
Ming-Sheng Zhou et al. · Diabetology & Metabolic Syndrome · 2014
DOI 10.1186/1758-5996-6-12
narrative_reviewCited 203×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Sodium retention is an evolutionarily conserved mechanism linked to insulin resistance, where insulin promotes sodium reabsorption in the kidney, and high salt intake exacerbates hypertension in salt-sensitive individuals with insulin resistance.Good
- Insulin resistance and hypertension are evolutionary adaptations (thrifty genotype) designed to conserve energy and sodium during famine, infection, or stress, which become maladaptive in modern environments characterized by caloric and sodium abundance.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →